In this introductory video on head and neck cancer, radiation oncologist Dr. Carryn Anderson of the University of Iowa defines head and neck cancers. Listen as Dr. Anderson explains typical symptoms and common causes. She also describes treatment standards and lists the customary members of your healthcare team. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo
Author: admin
Mohamad Mohty, MD, PhD, from Saint-Antoine Hospital, Paris, France and Arnon Nagler, MD, from the Sheba Medical Center, Tel Hashomer, Israel, discuss the highlights from the second day of the 2016 World Congress on Controversies in Multiple Myeloma (COMy) held in Paris, France. First, Prof Nagler highlights the presentations that focused on the current situation in Asia and how therapies for multiple myeloma (MM) all around the world are improving. Prof Mohty also discusses the trials that are being run in China. Prof Nagler and Prof Mohty then discuss the Patient Advocate Meeting and the importance of the patient voice…
Jesús San Miguel, MD, PhD, from the University of Navarra, Navarra, Spain gives an overview of immunomodulatory drugs (IMiDs) thalidomide, lenalidomide and pomalidomide for multiple myeloma (MM). According to Prof San Miguel, these drugs have reinforced the value of the immune system. The tumor cells use various mechanisms to evade immune system control, such as the PD-1/PDL-1 pathway. The monoclonal antibody pembrolizumab can release this particular break on the immune system. Prof San Miguel explains how preliminary data shows, that at the time of minimal residual disease (MRD) and relapse, the PD-1 is expressed on the T-cells and PDL-1 on…
Philippe Moreau, MD from the University Hospital of Nantes, Nantes, France gives an overview of a prospective comparison on PET-CT and MRI in multiple myeloma (MM). The primary endpoint of the trial (NCT01309334) was to compare MRI and PET-CT in regard to the number of bone lesions at diagnosis and the secondary endpoint was to look at the prognostic impact of both imaging techniques. According to Prof Moreau, both techniques are equally effective at identifying the number bone lesions and PET-CT was able to predict progression-free survival (PFS). Prof Moreau argues that PET-CT is a very important imaging technique. Recorded…
Jean-Luc Harousseau, MD, from the University of Nantes, Nantes, France gives two message to stakeholders, such as pharmaceutical companies, the payers, such as healthcare providers, and doctors concerning the access to and affordability of novel drugs in multiple myeloma (MM). According to Prof Harousseau, the stakeholders should find a fair price for the drugs and act transparently. The payers should focus on the patient pathway and healthcare organization. Further, doctors should not only consider the efficacy but also the efficiency. His second message to the stakeholders, payers and doctors is to work together rather than against each other. Recorded at…
Paula RodrÃguez, MD, PhD from the University Clinic of Navarra, Pamplona, Spain gives an overview of the two main PD-1 checkpoint inhibitors, nivolumab and pembrolizumab. A Phase I trial of nivolumab as a single agent for a group of hematological malignancies, showed an overall response rate of around 40% for diffuse large B-cell and follicular lymphoma (NCT02038933 and NCT02038946) and an overall response rate of 87% in Hodgkin lymphoma (NCT01592370). In multiple myeloma (MM), nivolumab as a single agent only achieved a stabilization of the disease and according to Dr RodrÃguez, these drugs need to be combined in MM. Dr…
Michel Delforge, MD, PhD from the University Hospital Leuven, Leuven, Belgium provides an overview of the approval of proteasome inhibitors in relapsed/refractory multiple myeloma (MM) since 2003. Prof Delforge first discusses bortezomib, which was first approved by the US Food and Drug Administration (FDA) in 2003 and later, was approved for the use as upfront therapy in Europe and the US. Based on the success story of bortezomib, second generation proteasome inhibitors such as carfilzomib in combination with lenalidomide and dexamethasone, have been approved. Ixazomib, an oral proteasome inhibitor, has also been approved. Recorded at the 2016 World Congress on…
Hervé Avet-Loiseau, MD, PhD from the Cancer Research Center of Toulouse, Toulouse, France discusses his talk on prognostic factors in multiple myeloma (MM) held at the 2016 World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France. According to Prof Avet-Loiseau, it is important to categorize the prognostic factors. Some prognostic factors, such as age and co-morbidities, are related to the patient. He further discusses prognostic factors related to the tumor clone, such as cytogenetics, and prognostic factors that are only identified after treatment, i.e. response to treatment. Prof Avet-Loiseau argues that in light of minimal residual disease (MRD)…
In this presentation from the 2016 “European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes”, Dr. Alessandro M. Vannucchi discusses the use of novel agents and combination therapies in the treatment of myelofibrosis (MF). A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7210 © 2016 Imedex, LLC.
In this presentation from the 2016 “European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes”, Dr. Nicolaus Kröger discusses the influence of mutational status on the timing, outcome and post-transplant management of patients with myelofibrosis (MF). A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7210 © 2016 Imedex, LLC.
In this presentation from the 2016 “European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes”, Dr. Mary F. McMulllin discusses how to manage side effects of JAK inhibitors in the treatment of myelofibrosis (MF). A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7210 © 2016 Imedex, LLC.
In this presentation from the 2016 “European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes”, Dr. Srdan Verstovsek provides an update on several JAK inhibitors in development for use in the treatment of myelofibrosis (MF). A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7210 © 2016 Imedex, LLC.
In this presentation from the 2016 US Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, held August 26-27 in Alexandria, VA, Dr. Eilliot Winton examines whether there is any real clinical utility in utilizing mutation-based risk stratification approaches in the treatment of patients with myelofibrosis. Earn accreditation for a related activity at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7221 © 2016 Imedex, LLC.
In this presentation from the 2016 “European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes”, Dr. Theo De Witte discusses novel strategies to prevent relapse of myelodysplastic syndromes (MDS) after allogeneic transplantation has been performed. A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7210 © 2016 Imedex, LLC.
In this presentation from the 2016 “European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes”, Dr. Michael Pfeilstöcker discusses newer therapeutic agents for use in the treatment of myelodysplastic syndromes (MDS) when hypomethylating agents (HMAs) fail. A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7210 © 2016 Imedex, LLC.
In this presentation from the 2016 “European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes”, Dr. Martin Jädersten provides an update on the use of erythropoiesis-stimulating agents and other growth factors in the treatment of low-risk myelodysplastic syndromes (MDS). A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7210 © 2016 Imedex, LLC.
In this presentation from the 2016 “European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes”, Dr. Fabio Efficace discusses quality of life as a treatment goal in myelodysplastic syndromes (MDS). A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7210 © 2016 Imedex, LLC.
In this presentation from the 2016 “European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes”, Dr. Torsten Haferlach discusses whether mutational profiling in patients with myelodysplastic syndromes (MDS) is ready for everyday use in the clinic. A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7210 © 2016 Imedex, LLC.
In this presentation from the 2016 US Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, held August 26-27 in Alexandria, VA, Dr. Ruben A. Mesa discusses the pros and cons of therapy for “early” myelofibrosis. Earn accreditation for a related activity at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7221 © 2016 Imedex, LLC.
In this presentation from the 2016 “European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes”, Dr. Gunnar BirgegÃ¥rd discusses what we have learned so far regarding the use of JAK inhibitors in the treatment of essential thrombocythemia (ET) and polycythemia vera (PV). A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7210 © 2016 Imedex, LLC.
In this presentation from the 2016 “European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes”, Dr. Jean-Jacques Kiladjian provides and update on long-acting interferons for the treatment of myeloproliferative neoplasms. A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7210 © 2016 Imedex, LLC.
In this presentation from the 2016 US Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, held August 26-27 in Alexandria, VA, Dr. Michael Kroll discusses the diagnosis and treatment of splanchnic vein thrombosis and myeloproliferative neoplasms (MPN).
In this presentation from the 2016 “European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes”, Dr. Tiziano Barbui discusses the updated World Health Organization (WHO) diagnostic criteria for myeloproliferative neoplasms. A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7210 © 2016 Imedex, LLC.
In this presentation from the 2016 “European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes”, Dr. Rajko Kuec discusses the interplay of somatic and germline variants in myeloproliferative neoplasms. A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7210 © 2016 Imedex, LLC.
In this presentation from the 2016 “European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes”, Dr. Marie-Caterine Le Bousse-Kerdilès discusses cytokines, cells, and inflammation in myeloproliferative neoplasms (MPN). A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7210 © 2016 Imedex, LLC.
In this presentation from the 2016 “European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes”, Dr. Mario Cazzola discusses somatic mutations of RNA splicing machinery in myelodysplastic syndromes (MDS). A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7210 © 2016 Imedex, LLC.
In this presentation from the 2016 “European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes”, Dr. Carol Gambacorti-Passerini discusses the genetic basis of atypical chronic myeloid leukemia (CML). A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7210 © 2016 Imedex, LLC.
In this presentation from the 2016 “European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes”, Dr. Eric Solary discusses the genetic basis of chronic myelomonocytic leukemia (CMML). A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7210 © 2016 Imedex, LLC.
This discussion between the chairs of the 2016 “European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes” provides a summary of the most intriguing and clinically applicable topics and data, outlines key learning points, and reinforces the take-home messages from the Congress. A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7210 © 2016 Imedex, LLC.
In this presentation from the “MPN Therapies: Emerging Concepts for Enhanced Outcomes” symposium, Dr. Alessandro M. Vannucchi argues that early-stage myelofibrosis should be treated. A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7212 © 2016 Imedex, LLC.
In this presentation from the “MPN Therapies: Emerging Concepts for Enhanced Outcomes” symposium, Dr. Paola Guglielmelli discusses the clinical benefit of JAK2 inhibitors in patients with myeloproliferative neoplasms. A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7212 © 2016 Imedex, LLC.
In this presentation from the “MPN Therapies: Emerging Concepts for Enhanced Outcomes” symposium, Dr. Franscisco Cervantes discusses emerging JAK2 inhibitor combination treatment strategies for patients with myelofibrosis. A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7212 © 2016 Imedex, LLC.
In this presentation from the “MPN Therapies: Emerging Concepts for Enhanced Outcomes” symposium, Dr. Mario Cazzola argues that early-stage myelofibrosis should be not treated but should be observed. A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7212 © 2016 Imedex, LLC.
Metastatic Colorectal Cancer” symposium, Eric Van Cutsem discusses the emerging treatment options for metastatic colorectal cancer patients in the late-line setting. A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7200 © 2016 Imedex, LLC.
In this presentation from the “Individualizing Late-Line Treatment for Patients with Metastatic Colorectal Cancer” symposium, Dr. Howard S. Hochster discusses the management of adverse events associated with third-line treatments for metastatic colorectal cancer. A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7200 © 2016 Imedex, LLC.
This discussion presents a discussion between world-renowned thought leaders Axel Grothey, Howard Hochster, and Eric Van Cutsem, who elucidate the effective implementation of new late-line CRC treatments in the clinical setting. A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7199 © 2016 Imedex, LLC.
In this webcast, Dr. David P. Steensma discusses the most pertinent information presented on leukemia and myeloid disorders during the 2016 Great Debates and Updates in Hematologic Malignancies meeting. A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.
In this webcast, Dr. John P. Leonard discusses the most pertinent information presented on lymphoma during the 2016 Great Debates and Updates in Hematologic Malignancies meeting. A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.
In this webcast, Dr. Robert Z. Orlowski discusses the most pertinent information presented on multiple myeloma during the 2016 Great Debates and Updates in Hematologic Malignancies meeting. A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.
Advancements in breast cancer care continue to rapidly evolve and the San Antonio Breast Cancer Symposium (SABCS) is the premier annual forum for exchange of new scientific and clinical information. However, not all healthcare professionals have the opportunity to attend this meeting and even those that do attend often can benefit from taking a deeper dive into the relevance of the data in a smaller venue in which more intimate faculty and peer interactions can take place. This is the role of the annual Best of San Antonio – Breast Cancer: Bench to Bedside meetingto help practicing clinicians interpret the…
Polycythemia vera (PV) is characterized by erythrocytosis, thrombocytosis, and/or leukocytosis with a broad-range of disease-related symptoms that impact the overall health and everyday quality of life of patients. The identification of the high frequency JAK2V617F mutation in patients with PV defines a molecular target for therapeutic intervention. This interactive case-based activity, is designed to complement, accelerate, and reinforce application of knowledge and skills amongst healthcare professionals interested in optimal management strategies for patients with PV. A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7194 © 2016 Imedex, LLC.
Cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors in combination with antiestrogen therapy work to combat endocrine resistance in women with estrogen receptor-positive (ER+) metastatic breast cancer. One CDK 4/6 inhibitor is FDA approved and 2 others are in Phase 3 development for this use. This activity discusses the ongoing and planned clinical trials for abemaciclib and ribociclib in ER+ metastatic breast cancer, as well as the future implications for this class of agents in this patient population. A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7171 © 2016 Imedex, LLC.
Cyclin-dependent kinase (CDK) 4/6 inhibitors in combination with antiestrogen therapy work to combat endocrine resistance in women with estrogen ER+ metastatic breast cancer. One CDK 4/6 inhibitor is FDA approved and 2 others are in Phase 3 development for breast cancer. This activity discusses clinical data on the efficacy and safety of the FDA-approved CDK 4/6 inhibitor, palbociclib, in combination with letrozole in ER+ metastatic breast cancer. A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7170 © 2016 Imedex, LLC.
The cyclin-dependent kinase (CDK) pathway is critical to cell cycle entry. In many tumor types, including breast cancer, there is dysregulation of this pathway. This activity describes the rationale and mechanism for inhibiting this dysregulated pathway in estrogen receptor-positive (ER+) metastatic breast cancer using selective CDK 4/6 inhibitors. A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7169 © 2016 Imedex, LLC.
In this presentation from the “17th Annual Congress: Perspectives in Lung Cancer”, Dr. Paul Baas discusses updates in the systemic treatment of pleural mesothelioma. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7211 © 2016 Imedex, LLC.
In this presentation from the “17th Annual Congress: Perspectives in Lung Cancer”, Dr. Elisabeth Quoix discusses the optimatl treatment of elderly patients with non-small cell lung cancer (NSCLC). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7211 © 2016 Imedex, LLC.
In this presentation from the “17th Annual Congress: Perspectives in Lung Cancer”, Dr. Maurice Perol discusses the targeting of angiogenesis for the treatment of lung cancer. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7211 © 2016 Imedex, LLC.
In this presentation from the “17th Annual Congress: Perspectives in Lung Cancer”, Dr. Pieter E. Postmus discusses the maintenance paradigm for the treatment of non-squamous non-small cell lung cancer (NSCLC). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7211 © 2016 Imedex, LLC.
In this presentation from the “17th Annual Congress: Perspectives in Lung Cancer”, Dr. Lucio Crino? discusses the first- and second-generation ALK inhibitors for the treatment of lung cancer. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7211 © 2016 Imedex, LLC.
In this presentation from the “17th Annual Congress: Perspectives in Lung Cancer”, Dr. Rafal Dziadziuszko discusses strategies for overcoming KRAS mutations. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7211 © 2016 Imedex, LLC.